C1 esterase inhibitor [human] liquid — Competitive Intelligence Brief

C1 esterase inhibitor [human] liquid (C1 esterase inhibitor [human] liquid) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Serine protease inhibitor; plasma-derived protein replacement. Area: Immunology; Rare Genetic Disorders.

phase 3 Serine protease inhibitor; plasma-derived protein replacement C1 esterase inhibitor (C1-INH); Factor XIIa, Factor XIa, Kallikrein Immunology; Rare Genetic Disorders Small molecule

Target snapshot

C1 esterase inhibitor [human] liquid (C1 esterase inhibitor [human] liquid) — Shire. C1 esterase inhibitor replaces or augments the deficient or dysfunctional C1 inhibitor protein, which normally suppresses excessive activation of the contact system and complement cascade.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
C1 esterase inhibitor [human] liquid TARGET	C1 esterase inhibitor [human] liquid	Shire	phase 3	Serine protease inhibitor; plasma-derived protein replacement	C1 esterase inhibitor (C1-INH); Factor XIIa, Factor XIa, Kallikrein
Nafamostat Mesilate	Nafamostat Mesilate	Chong Kun Dang Pharmaceutical	marketed	Serine protease inhibitor	Serine proteases (thrombin, factor Xa, kallikrein, trypsin)
C1 Esterase Inhibitor (Human)	C1 Esterase Inhibitor (Human)	Shire	marketed	Serine protease inhibitor; complement regulator	C1 esterase inhibitor (C1-INH); Factor XIIa; plasma kallikrein
C1 inhibitor (human) [C1 INH]	C1 inhibitor (human) [C1 INH]	Shire	marketed	Complement inhibitor / Serine protease inhibitor	C1s protease / Classical complement pathway
Aprotinin (inhaled)	Aprotinin (inhaled)	Fundacion del Hospital Nacional de Paraplejicos para la Investigacion y la Integracion	phase 3	Serine protease inhibitor	Kallikrein, plasmin, trypsin, and other serine proteases
Low-volume C1-esterase inhibitor	Low-volume C1-esterase inhibitor	CSL Behring	phase 3	Serine protease inhibitor / Complement regulator	C1-esterase inhibitor (C1-INH protein)
Higher-volume C1-esterase inhibitor	Higher-volume C1-esterase inhibitor	CSL Behring	phase 3	Serine protease inhibitor / Complement regulator	C1-esterase (C1s), Factor XIIa, Plasma kallikrein

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Serine protease inhibitor; plasma-derived protein replacement class)

1. Shire · 1 drug in this class